The typical cost of developing new medications may not be as high as generally believed, with a few ultra-costly medications ...

Just a month after announcing a $115 million series D financing to advance its lead assets, Maze Therapeutics is looking to ...

A biopharmaceutical company and its executives misled investors ahead of its 2024 initial public offering about a key ...

QPS Holdings, a contract research organization with offices in the U.S., Asia and Europe, has named Ryght AI its ...

A biotech company is currently developing and seeking FDA approval for a drug that could extend a dog's lifespan.

The FDA has approved a first-of-its-kind treatment for dry age-related macular degeneration (AMD), a leading cause of blindness in adults over 55.

Denali’s medicine and a similar one from Calico Life Sciences and AbbVie were not much different than a placebo, bringing the ...

Independence Blue Cross has begun excluding coverage for 18 months for therapies — but not cancer drugs — that have an ...

Neurosense entered a binding term sheet with a global pharmaceutical company to advance development and commercialization of ...

When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion in sales in 2023, it shows no signs of slowing down, much to the delight of its Danish manufacturer, Novo ...

Two posters presented at the 2024 American Society of Hematology meeting reported real-world outcomes data for patients ...

An Institute for Value-Based Medicine regional event in Houston, Texas, covered inconsistencies with the integration of precision medicine in oncology practices, the evolution of treatment for ...